Status:
UNKNOWN
Famciclovir in Multiple Sclerosis
Lead Sponsor:
Queen Mary University of London
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a proof-of-concept study in 30 patients with established Relapsing Remitting Multiple Sclerosis (RRMS). IMP is Famciclovir. It is a phase II type A open label study. Each individuals participa...
Eligibility Criteria
Inclusion
- Diagnosed with MS
- Males and females aged over 18
- Taking Natalizumab (Tysabri) for the treatment of MS,
- Be able to provide informed consent to take part in this study.
- Female patients of childbearing potential (defined in section 13.4) must be willing to follow protocol contraceptive requirements.
Exclusion
- Taking MS disease modifying treatment other than natalizumab (Tysabri)
- On no treatment for MS
- Taking additional immunomodulatory agents (either for MS treatment or other reasons)
- Has received a course of high dose oral or intravenous steroids within 3 months of study entry. The use of low dose (total daily dose \<10mg) and/or the use of topical steroids will not act as an exclusion criteria.
- Taking antiviral or antiretroviral medication for any reason
- Known allergy to penciclovir, acyclovir, valaciclovir or famciclovir
- Taking probenecid
- Significant renal (CKD 3 or 4) and/or liver (ALT\>3x ULN) impairment
- Pregnant, or unwilling to take measures to prevent pregnancy
- Breastfeeding
Key Trial Info
Start Date :
November 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 25 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05283551
Start Date
November 25 2020
End Date
November 25 2023
Last Update
March 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal London Hospital, Barts Health NHS Trust
London, United Kingdom, E1 1BB